These results suggested that, in thyroid carcinoma (THCA), lung adenocarcinoma (LUAD), liver hepatocellular carcinoma (LIHC), overall glioma, and kidney renal clear cell carcinoma (KIRC), patients with a lower RAD51 expression were much more likely to respond to ICB immunotherapy. This evidence concerns the gene RAD51 and lung adenocarcinoma.